Loading
Immunotherapy and Immune Responses / Cancer Cells and Metastasis · Journal article
Cancer Immunology Immunotherapy · September 6, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a single-institution retrospective study that applies a computational immune-scoring algorithm (TIMMUSCORA) to genomic and transcriptomic data from 394 cancer patients to explore associations between chromosomal instability parameters and immunosuppression in the tumour microenvironment. The work is exploratory: it identifies correlations between specific mutations (TP53, EGFR), genomic features (whole genome duplication, chromothripsis), and immune cell signatures, but lacks independent validation, functional evidence, or prospective clinical outcome data to support clinical utility.
Retrospective observational cohort study with correlative genomic and transcriptomic analysis. 394 cancer patients with available whole genome sequencing and gene expression profiling data; specific cancer types, stage, prior treatment, and key eligibility criteria not detailed in abstract. Intervention: Application of TIMMUSCORA algorithm to WGS and GEP data to score immune status in relation to CIN parameters. Compared with: Comparison of immune profiles and gene expression patterns in WGD-positive vs WGD-negative and chromothripsis-positive vs chromothripsis-negative tumours. n = 394.
Most CIN-related parameters (TMB, SV, MSI score, ploidy, HRD score, chromothripsis, WGD) were associated with low TIMMUSCORA scores indicating immunosuppression in 394 cancer patients WGD- or CT-positive tumours showed down-regulation of B cell markers and myeloid cell markers, and up-regulation of NKG2D gene expression TP53 and EGFR mutation events were associated with WGD and low TIMMUSCORA scores
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The findings suggest TIMMUSCORA may help characterize immune status in chromosomally unstable tumours, potentially informing patient stratification for immunotherapy. However, clinical utility remains unproven: the work is correlative and requires validation in independent cohorts and prospective assessment of treatment response or survival outcomes before clinical implementation.
Single-centre observational study applying a previously developed algorithm to correlative genomic and immune data without experimental validation, prospective clinical outcome assessment, or comparison to an independent cohort.
As stated by the source record.
Quoted from the source exactly as published.
The findings suggest TIMMUSCORA may help characterize immune status in chromosomally unstable tumours, potentially informing patient stratification for immunotherapy. However, clinical utility remains unproven: the work is correlative and requires validation in independent cohorts and prospective assessment of treatment response or survival outcomes before clinical implementation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Chromosomal instability (CIN) is associated with immunosuppression in the tumor microenvironment (TME), resulting in cancer progression, metastasis, and resistance to immune checkpoint blockade therapy. We previously established a tumor immune status scoring algorithm (TIMMUSCORA) in which the immune status in the TME is evaluated numerically from activation to suppression. In the present study, we clarified the relationships between structural variation-related parameters and immunological features by applying TIMMUSCORA to solid cancers. Whole genome sequencing (WGS) and gene expression profiling (GEP) data were obtained from 394 cancer patients, and CIN-related parameters, such as the tumor mutation burden (TMB), structural variant (SV), microsatellite instability (MSI) score, ploidy, homologous recombination deficiency score, and chromothripsis (CT) and whole genome duplication (WGD) scores, were assessed. The TIMMUSCORA system demonstrated that most CIN-related parameters contributed to the low TIMMUSCORA score implicating an immunosuppressive state. Comparisons of differentially expressed genes between WGD- or CT-positive and -negative tumors showed the down-regulation of B cell markers, the down-regulation of myeloid cell markers, and the up-regulation of the NKG2D gene. In addition, the following novel observations were verified; (1) TP53 and EGFR mutation events can be associated with WGD and low TIMMUSCORA scores, and (2) NK cell activation and cancer–testis antigen gene up-regulation might be associated with CT. These results suggest that TIMMUSCORA might be useful tool evaluating immune status of CIN-harboring tumors. In future, the specific mechanism for CIN-associated immunosuppression in the tumor can be explored and clarified.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.